-
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
Groen, K., Smits, F., Nasserinejad, K., Levin, M-D., Regelink, J. C., Timmers, G-J., de Waal, E. G. M., Westerman, M., Velders, G. A., de Heer, K., Leys, R. B. L., van Kampen, R. J. W., Stege, C. A. M., Seefat, M. R., Nijhof, I. S., van der Spek, E., Klein, S. K., van de Donk, N. W. C. J., Ypma, P. F. & Zweegman, S., 1 Jul 2024, In: HemaSphere. 8, 7, e85.Research output: Contribution to journal › Comment/Letter to the editor › Academic
-
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
HOVON CLL Working Group, 28 Sept 2023, In: Blood. 142, 13, p. 1131-1142 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
Groen, K., Stege, C. A. M., Nasserinejad, K., de Heer, K., van Kampen, R. J. W., Leys, R. B. L., Thielen, N., Westerman, M., Wu, K-L., Ludwig, I., Issa, D. E., Velders, G. A., Vekemans, M-C., Timmers, G-J., de Boer, F., Tick, L. W., Verbrugge, A., Buitenhuis, D., Cunha, S. M., van der Spek, E., & 9 others, 1 Sept 2023, In: EClinicalMedicine. 63, 102167.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
